Genus Oncology, Inc. (Genus) is being formed to discover, develop and commercialize new anti-cancer agents that target the Mucin 1 (MUC1) protein. MUC1 is a protein that is important in the regulation of cell activities related to both growth and death. MUC1 is over-expressed by most carcinomas of the breast, prostate, lung, colon, pancreas and ovary, causing uncontrolled growth. MUC1 is also over expressed by specific hematologic malignancies, including multiple myeloma, non-Hodgkins lymphoma and acute myeloid leukemia. Tumors which express high levels of MUC1 represent over 65% of all tumors diagnosed annually in the United States and other countries
